Delayed Puberty Medical Services in China

Delayed puberty is a clinical condition characterized by the absence of secondary sexual development by age 13 in girls (no breast development) or age 14 in boys (no testicular enlargement ≥4 mL or 2.5 cm in length). It represents a deviation from the normal pubertal timing spectrum and may reflect either a benign, self-limited variant—constitutional delay of growth and puberty (CDGP)—or an underlying pathological disorder affecting the hypothalamic-pituitary-gonadal (HPG) axis. Pathogenesis is broadly categorized into three groups: central (hypogonadotropic) causes—including functional suppression (e.g., chronic illness, malnutrition, excessive exercise, psychosocial stress), congenital deficiencies (e.g., Kallmann syndrome, idiopathic hypogonadotropic hypogonadism), or acquired lesions (e.g., craniopharyngioma, traumatic brain injury); peripheral (hypergonadotropic) causes—such as primary gonadal failure (e.g., Turner syndrome in females, Klinefelter syndrome in males, chemotherapy-induced gonadal damage); and other endocrine disorders—including hypothyroidism, hyperprolactinemia, Cushing syndrome, or growth hormone deficiency. Epidemiologically, delayed puberty affects approximately 2–3% of adolescents, with CDGP accounting for ~70–80% of cases in males and ~40–50% in females; true pathological causes are less common but require timely identification to prevent long-term sequelae. Key risk factors include family history of delayed puberty, chronic systemic diseases (e.g., inflammatory bowel disease, cystic fibrosis), eating disorders, intense athletic training, genetic syndromes, and prior cranial irradiation or chemotherapy. Psychosocial impact is profound: affected adolescents often experience heightened anxiety, social withdrawal, low self-esteem, body image distress, and academic disengagement due to perceived physical immaturity relative to peers. Untreated pathological forms may lead to osteopenia, short adult stature, infertility, and metabolic complications later in life. Early evaluation—including detailed history, auxology, bone age assessment (hand-wrist radiograph), hormonal profiling (LH, FSH, estradiol/testosterone, AMH, inhibin B, thyroid function, prolactin), and targeted imaging (e.g., pituitary MRI if central cause suspected)—is essential to differentiate CDGP from organic disease. Multidisciplinary care involving pediatric endocrinologists, psychologists, nutritionists, and reproductive specialists optimizes outcomes and supports holistic quality of life restoration.

Delayed puberty is defined as the absence of testicular enlargement (testicular volume <4 mL or diameter <2.5 cm) in boys by age 14 years, or lack of breast development (Tanner stage B2) in girls by age 13 years. It may represent a benign constitutional delay of growth and puberty (CDGP), functional hypogonadotropic hypogonadism (e.g., due to chronic illness, malnutrition, excessive exercise, or psychosocial stress), or organic disorders including congenital hypogonadotropic hypogonadism (CHH), hypergonadotropic hypogonadism (e.g., Klinefelter or Turner syndromes), central nervous system tumors, or genetic syndromes. Accurate diagnosis—requiring detailed history, physical examination, bone age assessment, hormonal profiling (LH, FSH, testosterone/estradiol, AMH, inhibin B), pituitary MRI when indicated, and genetic testing (e.g., ANOS1, FGFR1, PROKR2, CHD7)—is essential before initiating therapy.

Conservative management is first-line for confirmed constitutional delay. This includes comprehensive nutritional optimization—ensuring adequate caloric intake, protein, zinc, vitamin D, and iron—particularly critical in adolescents with relative energy deficiency in sport (RED-S) or chronic gastrointestinal disease. Psychosocial support is integral: counseling addresses body image concerns, peer-related anxiety, academic stress, and potential depression or social withdrawal. Regular longitudinal monitoring every 6–12 months assesses growth velocity, pubertal staging (Tanner scale), bone age progression, and psychosocial adaptation. In CDGP, spontaneous puberty typically emerges within 1–2 years; observation without intervention remains appropriate when no red flags (e.g., anosmia, micropenis, cryptorchidism, neurologic symptoms, or growth failure) are present.

Pharmacologic intervention is indicated when delayed puberty causes significant psychosocial distress, compromises peak bone mass accrual, or reflects underlying pathology. For boys with CDGP or mild CHH, low-dose testosterone enanthate or cypionate (25–50 mg intramuscularly every 4 weeks for 4–6 months) induces virilization and stimulates endogenous gonadotropin secretion via hypothalamic-pituitary feedback modulation. In girls, estradiol valerate (0.5–1.0 mg orally daily for 6–12 months, gradually increased to adult replacement doses) initiates breast development and uterine priming; progesterone (e.g., micronized progesterone 100 mg daily for 10–12 days per cycle) is added after 12–18 months or upon breakthrough bleeding to induce cyclical endometrial shedding. For patients with documented CHH requiring fertility preservation, pulsatile GnRH therapy (via portable subcutaneous pump) or gonadotropin regimens (hCG + recombinant FSH) are employed under specialist supervision. Aromatase inhibitors (e.g., letrozole) are not recommended for routine use in delayed puberty due to insufficient long-term safety data and lack of proven benefit on final height or bone health.

Surgical treatment is rarely indicated for delayed puberty itself but becomes necessary when an underlying structural lesion is identified. Pituitary adenomas, craniopharyngiomas, or hypothalamic hamartomas causing compressive hypogonadotropic hypogonadism require neurosurgical evaluation. Transsphenoidal resection is standard for non-invasive, hormonally inactive microadenomas or symptomatic macroadenomas. In cases of ectopic posterior pituitary or optic pathway gliomas, multidisciplinary neuro-oncology input guides timing and modality of intervention. Cryptorchidism—present in up to 15% of boys with delayed puberty—warrants orchidopexy before age 18 months if persistent beyond infancy; late correction (>10 years) does not reverse germ cell loss but mitigates malignancy risk. Surgical sex assignment is never indicated solely for delayed puberty and requires rigorous ethical review only in complex differences of sex development (DSD) contexts.

China offers distinct advantages in the multidisciplinary management of delayed puberty. First, integrated endocrine-pediatric-gynecologic-neurosurgical teams operate within tiered national healthcare frameworks, enabling rapid referral from primary care to tertiary centers such as Peking Union Medical College Hospital or Shanghai Children’s Medical Center. Second, China’s National Rare Diseases Registry and Genomic Initiative facilitate timely access to next-generation sequencing panels for CHH and DSD diagnostics, reducing diagnostic odysseys. Third, cost-effective biosimilar gonadotropins and domestically manufactured estradiol/testosterone formulations improve treatment accessibility. Fourth, standardized clinical pathways endorsed by the Chinese Endocrine Society ensure evidence-based, protocol-driven care across provinces. Fifth, digital health platforms (e.g., WeDoctor, Ping An Good Doctor) support remote monitoring of growth parameters, medication adherence, and mental health screening—critical for rural populations. Finally, large-scale longitudinal cohort studies (e.g., the China Adolescent Growth Project) generate real-world data on natural history and treatment outcomes unique to East Asian phenotypes.

Recovery and long-term follow-up emphasize metabolic and skeletal health maintenance. Patients completing induction therapy should transition to full sex hormone replacement aligned with chronological age and bone maturation—testosterone (100–150 mg IM weekly or transdermal gel) or estradiol (1–2 mg/day oral or transdermal) plus cyclic progesterone. Dual-energy X-ray absorptiometry (DXA) is recommended at completion of puberty to assess bone mineral density (BMD); those with Z-scores <−2.0 warrant calcium (1,200 mg/day), vitamin D (1,000–2,000 IU/day), weight-bearing exercise prescription, and endocrinology re-evaluation. Fertility counseling must begin early: semen analysis in postpubertal males and ovarian reserve testing (AMH, AFC) in females guide future reproductive planning. Annual assessments of cardiovascular risk factors (lipid profile, glucose, blood pressure), thyroid function, and pituitary axes remain essential, particularly in CHH or prior cranial irradiation. Psychosocial resilience is reinforced through peer-support networks, school liaison services, and cognitive-behavioral strategies targeting self-efficacy and identity integration. With timely, individualized intervention, >95% of adolescents with constitutional delay achieve normal adult height, sexual function, and psychosocial adaptation; even those with organic causes attain high-quality life outcomes when managed within China’s evolving precision endocrinology ecosystem.